In the sensitivity analysis, higher albumin levels remained to be associated with decreased overall cancer risks (Q2 vs. Q1: HR 0.93, 95% CI 0.76–1.13; Q3 vs. Q1: HR 0.83, 95% CI 0.69–0.99; Q4 vs. Q1: HR 0.75, 95% CI 0.61–0.91), and significantly lower risk of liver cancer was found related to higher albumin levels (Q2 vs. Q1: HR 0.49, 95% CI 0.25–0.97; Q3 vs. Q1: HR 0.40, 95% CI 0.22–0.74; Q4 vs. Q1: HR 0.41, 95% CI 0.21–0.78). The gene discussed is ALB; the disease is liver cancer.